Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology (NASDAQ:VIR) Stock Bumped Down to "Strong Sell" by Zacks Research - Markets Daily
Vir Biotechnology (NASDAQ:VIR) Cut to "Strong Sell" at Zacks Research
How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology's (VIR) Investment Narrative
VIR Maintains by HC Wainwright & Co. -- Price Target Raised to $
Vir Biotechnology (NASDAQ:VIR) Given New $22.00 Price Target at HC Wainwright
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026 | Morningstar
Vir Biotechnology (VIR) Could Be 48% Undervalued Following Its CFO Appointment
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Bank of America Corp DE Acquires 1,142,539 Shares of Vir Biotechnology, Inc. $VIR
Reviewing Tango Therapeutics (NASDAQ:TNGX) and Vir Biotechnology (NASDAQ:VIR) - Stock Observer
VirBiotechnology news
Latest news
Show more
Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty
September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations
Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge
